HUM vs. MDLN: Humana vs. Medline Stock Comparison

Company Profile

Humana (HUM) and Medline (MDLN) both fall under the Health Care Equipment & Services industry group, but HUM is classified in Health Care Providers & Services while MDLN is classified in Health Care Equipment & Supplies.

Humana (HUM) has been public since December 31, 1981, giving it decades of market history across multiple cycles, while Medline (MDLN) listed only on December 17, 2025 and lacks comparable through-cycle data.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Medline (MDLN) reports a negative beta of -0.93, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Humana (HUM) has a non-negative beta of 0.62.

Risk-Adjusted Performance

Risk-Return Positioning

Both HUM and MDLN need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Both Humana (HUM) at 6.74% and Medline (MDLN) at 4.85% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

Both Humana (HUM) at 0.81% and Medline (MDLN) at 1.85% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

Both Humana (HUM) at 0.24% and Medline (MDLN) at 5.22% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.

Profitability Metrics

Growth

Only one side can be read here: Humana (HUM) reports revenue growth of 10.11%, ranked against its industry; Medline (MDLN) has no revenue growth figure this period.

Medline (MDLN) at 117.38% clears its industry range for EPS growth, a much stronger earnings trajectory than Humana (HUM) at -1.40%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

Humana (HUM) at 1.65 keeps current ratio within its industry’s typical mid-range, while Medline (MDLN) at 4.04 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.

Both Humana (HUM) at 0.68 and Medline (MDLN) at 0.65 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Medline (MDLN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Humana (HUM) reports a yield of 0.21%, ranking against industry peers normally.

Medline (MDLN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Humana (HUM) reports a payout of 34.54%, ranking against industry peers normally.

Dividend Metrics

Valuation

Humana (HUM) at 42.32 is near its industry’s usual P/E ratio, while Medline (MDLN) at 90.09 sits above its peer range — an unusually expensive price for MDLN’s trailing earnings.

Humana (HUM) at 0.34 sits in the cheaper P/S ratio quartile while Medline (MDLN) at 1.70 prices around its industry’s middle — HUM costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Humana (HUM) at 2.77 and Medline (MDLN) at 2.95 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics